[go: up one dir, main page]

MXPA05009885A - Nuevas triazolonas fusionadas y los usos de las mismas. - Google Patents

Nuevas triazolonas fusionadas y los usos de las mismas.

Info

Publication number
MXPA05009885A
MXPA05009885A MXPA05009885A MXPA05009885A MXPA05009885A MX PA05009885 A MXPA05009885 A MX PA05009885A MX PA05009885 A MXPA05009885 A MX PA05009885A MX PA05009885 A MXPA05009885 A MX PA05009885A MX PA05009885 A MXPA05009885 A MX PA05009885A
Authority
MX
Mexico
Prior art keywords
triazolones
novel fused
novel compounds
novel
fused
Prior art date
Application number
MXPA05009885A
Other languages
English (en)
Inventor
Yu Yan
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MXPA05009885A publication Critical patent/MXPA05009885A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

Esta invencion se refiere a nuevos compuestos que tienen el diagrama estructural (I) y a sus composiciones farmaceuticas y a sus metodos de uso. Estos nuevos compuestos proporcionan un tratamiento o profilaxis de cancer.
MXPA05009885A 2003-03-14 2004-03-10 Nuevas triazolonas fusionadas y los usos de las mismas. MXPA05009885A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US45507303P 2003-03-14 2003-03-14
US46769003P 2003-05-02 2003-05-02
US53634304P 2004-01-14 2004-01-14
PCT/SE2004/000351 WO2004081008A1 (en) 2003-03-14 2004-03-10 Novel fused triazolones and the uses thereof

Publications (1)

Publication Number Publication Date
MXPA05009885A true MXPA05009885A (es) 2005-12-05

Family

ID=32995996

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05009885A MXPA05009885A (es) 2003-03-14 2004-03-10 Nuevas triazolonas fusionadas y los usos de las mismas.

Country Status (10)

Country Link
US (1) US20070149560A1 (es)
EP (1) EP1613625A1 (es)
JP (1) JP2006520397A (es)
KR (1) KR20050119647A (es)
AU (1) AU2004220176A1 (es)
BR (1) BRPI0408256A (es)
CA (1) CA2519107A1 (es)
MX (1) MXPA05009885A (es)
NO (1) NO20054083L (es)
WO (1) WO2004081008A1 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7576085B2 (en) * 2002-09-23 2009-08-18 Schering Corporation Imidazopyrazines as cyclin dependent kinase inhibitors
JPWO2005063222A1 (ja) * 2003-12-26 2007-07-19 協和醗酵工業株式会社 Ｈｓｐ９０ファミリー蛋白質阻害剤
HUE040060T2 (hu) 2005-02-16 2019-02-28 Anacor Pharmaceuticals Inc Halogén-szubsztituált boronftalidok fertõzések kezelésére
US20080145358A1 (en) * 2005-02-18 2008-06-19 Astrazeneca Ab Method for Determining Responsiveness to Chk1 Inhibitors
WO2007058942A2 (en) * 2005-11-10 2007-05-24 Schering Corporation Imidazopyrazines as protein kinase inhibitors
MX335993B (es) * 2005-12-30 2016-01-07 Anacor Pharmaceuticals Inc Moleculas pequeñas que contienen boro.
BRPI0621279B1 (pt) 2005-12-30 2021-07-20 Anacor Pharmaceuticals, Inc Moléculas pequenas contendo boro
EP1978966A4 (en) * 2006-01-23 2010-11-10 Amira Pharmaceuticals Inc TRICYCLIC INHIBITORS OF 5-LIPOXYGENASE
TW200806670A (en) 2006-04-25 2008-02-01 Merck & Co Inc Inhibitors of checkpoint kinases
JO3598B1 (ar) * 2006-10-10 2020-07-05 Infinity Discovery Inc الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني
EP2094276A4 (en) * 2006-12-20 2011-01-05 Abbott Lab ANTIVIRAL COMPOUNDS
PL2114955T3 (pl) 2006-12-29 2013-06-28 Rigel Pharmaceuticals Inc Triazole podstawione mostkowanym bicyklicznym arylem oraz mostkowanym bicyklicznym heteroarylem użyteczne jako inhibitory Axl
WO2009002955A1 (en) * 2007-06-27 2008-12-31 Sanofi-Aventis U.S. Llc Process for the preparation of (2r)-2-[4-(7-bromo-2-quinolyloxy)phenoxy]propanoic acid
WO2009126691A1 (en) * 2008-04-09 2009-10-15 Infinity Pharmaceuticals, Inc Inhibitors of fatty acid amide hydrolase
CL2009001152A1 (es) 2008-05-13 2009-10-16 Array Biopharma Inc Compuestos derivados de n-(4-(cicloalquilo nitrogenado-1-il)-1h-pirrolo[2,3-b]piridin-3-il)amida, inhibidores de cinasa; proceso de preparacion; composicion farmaceutica; y su uso para el tratamiento de una enfermedad proliferativa.
WO2010004319A1 (en) * 2008-07-07 2010-01-14 Astrazeneca Ab Combination comprising 6-flu0r0-n- ((1s, 4s) - 4- (6-fluoro-2, 4-di0x0-1- (4'- (piperazin-1- ylmethyl) biphenyl- 3-yl) -1, 2-dihydropyrido [2, 3-d] pyrimidin-3 (4h) - yl) cyclohexyl) imidazo [1,2-a] pyridine -2- carboxamide or a salt
WO2010083465A1 (en) 2009-01-16 2010-07-22 Rigel Pharmaceuticals, Inc. Axl inhibitors for use in combination therapy for preventing, treating or managing metastatic cancer
US8614221B2 (en) 2009-03-11 2013-12-24 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
CA2757679A1 (en) 2009-04-07 2010-10-14 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
WO2010118159A1 (en) 2009-04-07 2010-10-14 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
BR112012019120A2 (pt) 2010-02-03 2016-06-28 Infinity Pharmaceuticais Inc forma sólida, composição farmacêutica, método de preparação do composto 1, método de tratamento de uma condição mediada por faah
WO2014060381A1 (de) 2012-10-18 2014-04-24 Bayer Cropscience Ag Heterocyclische verbindungen als schädlingsbekämpfungsmittel
JP2016503395A (ja) 2012-10-31 2016-02-04 バイエル・クロップサイエンス・アクチェンゲゼルシャフト 病害生物防除剤としての複素環化合物
KR102164612B1 (ko) * 2014-04-24 2020-10-12 동아에스티 주식회사 아졸계 화합물 및 이를 포함하는 선택적 안드로겐 수용체 효능제
EP3461480A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer
WO2023165528A1 (en) * 2022-03-01 2023-09-07 Insilico Medicine Ip Limited Diacylglycerol kinase (dgk) alpha inhibitors and uses thereof
AU2023227010A1 (en) 2022-03-01 2024-09-12 Insilico Medicine Ip Limited Diacylglycerol kinase (dgk) alpha inhibitors and uses thereof
CN119874716B (zh) * 2025-03-27 2025-07-15 上海隆盛化工有限公司 1-氯-6,8-二氟-7-异丙基苯并呋喃并[2,3-c]吡啶及其合成方法和应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3953457A (en) * 1972-07-28 1976-04-27 Eli Lilly And Company Agent for the control of plant-pathogenic organisms
US4252806A (en) * 1979-09-24 1981-02-24 Mead Johnson & Company Triazoloquinolones

Also Published As

Publication number Publication date
NO20054083D0 (no) 2005-09-02
JP2006520397A (ja) 2006-09-07
US20070149560A1 (en) 2007-06-28
NO20054083L (no) 2005-10-10
BRPI0408256A (pt) 2006-03-01
EP1613625A1 (en) 2006-01-11
CA2519107A1 (en) 2004-09-23
AU2004220176A1 (en) 2004-09-23
KR20050119647A (ko) 2005-12-21
WO2004081008A1 (en) 2004-09-23

Similar Documents

Publication Publication Date Title
MXPA05009885A (es) Nuevas triazolonas fusionadas y los usos de las mismas.
TW200508214A (en) Novel compounds
TW200716606A (en) Chemical compounds
PL1853602T3 (pl) Związki chemiczne
TW200800963A (en) Chemical compounds
SI1853588T1 (sl) Kemične spojine
BG66084B1 (bg) Циклопентаноиндоли, състави,съдържащи такива съединения и използването им
RS20050070A (en) Use of 1kb kinase inhibitors for the treatment of pain
TW200714604A (en) Substituted heterocycles and the uses thereof
TW200740812A (en) 1,4-Dihydropyridine-fused heterocycles, process for preparing the same, use and compositions containing them
TW200510427A (en) Novel fused heterocycles and uses thereof
MXPA05013549A (es) Derivados de tienopirimidina como inhibidores del canal de potasio.
SE0203825D0 (sv) Novel fused heterocycles and uses thereof
YU102503A (sh) Kondenzovani pirimidinski dhfr inhibitori kao antibakterijska sredstva
TW200604197A (en) New compounds
MXPA04002042A (es) Compuestos de bencimidazol sustituidos y su uso para el tratamiento del cancer.
UA90698C2 (en) Triazole substituted aminobenzophenone compounds
MY141233A (en) Enantiomers of selected fused heterocyclics and uses thereof
WO2005046587A3 (en) Preparation and composition of inter-alpha inhibitor proteins from human plasma for therapeutic use
MXPA04003755A (es) Endoprotesis vasculares.
EP1551388A4 (en) COMPOUNDS USEFUL IN THE TREATMENT OF CANCER, COMPOSITIONS AND METHODS COMPRISING THE SAME
DE60316128D1 (de) N-sulfonylurea-apoptosis-förderer
MX2007001954A (es) Heterociclicos fusionados seleccionados y sus usos.
MXPA03005374A (es) Carbazoles antitumorales.
TW200505440A (en) Novel fused triazolones and the uses thereof

Legal Events

Date Code Title Description
FA Abandonment or withdrawal